• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
New Actions on Actionable Mutations in Lung Cancers.肺癌可操作突变的新进展
Cancers (Basel). 2023 May 26;15(11):2917. doi: 10.3390/cancers15112917.
2
High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.在晚期非小细胞肺癌中，基于循环肿瘤 DNA 的下一代测序检测与组织下一代测序检测鉴定出的可操作基因组改变具有高度一致性：韩国肺液与有创性活检项目。
Cancer. 2021 Aug 15;127(16):3019-3028. doi: 10.1002/cncr.33571. Epub 2021 Apr 7.
3
Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.在常规检测中无 EGFR 和 ALK 改变的晚期非小细胞肺癌患者中，靶向 DNA 测序的获益。
Clin Lung Cancer. 2020 May;21(3):e182-e190. doi: 10.1016/j.cllc.2019.11.006. Epub 2019 Nov 21.
4
Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers.利用下一代测序技术对组织基因组和 ctDNA 之间的体细胞基因组改变进行相关性分析：肺癌和胃肠道癌的分析。
Mol Cancer Ther. 2018 May;17(5):1123-1132. doi: 10.1158/1535-7163.MCT-17-1015. Epub 2018 Mar 2.
5
Identifying a wide range of actionable variants using capture-based ultra-deep targeted sequencing in treatment-naive patients with primary lung adenocarcinoma.在初治的原发性肺腺癌患者中，使用基于捕获的超深度靶向测序来鉴定广泛的可操作变异。
Int J Clin Exp Pathol. 2020 Mar 1;13(3):525-535. eCollection 2020.
6
Comprehensive analysis of mutations in NSCLC patients in a real-world setting.对真实世界中NSCLC患者的突变进行综合分析。
Ther Adv Med Oncol. 2022 Jul 16;14:17588359221112474. doi: 10.1177/17588359221112474. eCollection 2022.
7
Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases.HER2阳性原发性乳腺癌及其脑转移瘤中的基因异质性和可靶向突变
Oncotarget. 2018 Apr 17;9(29):20617-20630. doi: 10.18632/oncotarget.25041.
8
Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.基于循环游离 DNA 的非小细胞肺癌治疗及变异等位基因频率的影响。
Clin Lung Cancer. 2021 Jul;22(4):e519-e527. doi: 10.1016/j.cllc.2020.11.007. Epub 2020 Dec 2.
9
IMPACT: a whole-exome sequencing analysis pipeline for integrating molecular profiles with actionable therapeutics in clinical samples.IMPACT：一种用于在临床样本中将分子图谱与可实施的治疗方法相结合的全外显子组测序分析流程。
J Am Med Inform Assoc. 2016 Jul;23(4):721-30. doi: 10.1093/jamia/ocw022. Epub 2016 Mar 28.
10
Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer.非小细胞肺癌中同时存在的潜在可操作致癌驱动因素
Front Oncol. 2021 Jun 16;11:665484. doi: 10.3389/fonc.2021.665484. eCollection 2021.

引用本文的文献

1
Multimodal Imaging to Improve Patient Selection and Optimize Treatment Planning and Delivery for Patients Undergoing Reirradiation: A Scoping Review.多模态成像改善再程放疗患者的患者选择并优化治疗计划与实施：一项范围综述
Curr Oncol Rep. 2025 Aug 20. doi: 10.1007/s11912-025-01708-9.
2
Genetic Ancestry and Lung Cancer in Latin American Patients: A Crucial Step for Understanding a Diverse Population.拉丁裔患者的遗传血统与肺癌：了解多样化人群的关键一步。
Clin Lung Cancer. 2025 Jul;26(5):e342-e352. doi: 10.1016/j.cllc.2025.03.004. Epub 2025 Mar 13.
3
Sex Difference in Disease-Related Adverse Events Post-Diagnosis of Lung Cancer Brain Metastases in Medicare Individuals ≥ 66 Years of Age.66岁及以上医疗保险参保个体肺癌脑转移诊断后疾病相关不良事件的性别差异
Cancers (Basel). 2024 Aug 28;16(17):2986. doi: 10.3390/cancers16172986.
4
Clinical Benefit from Docetaxel +/- Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy.对于在铂类双药化疗和免疫治疗中进展的转移性非小细胞肺癌患者，多西他赛±雷莫西尤单抗的临床获益与突变状态无关。
Cancers (Basel). 2024 Feb 26;16(5):935. doi: 10.3390/cancers16050935.
5
Real-World Outcomes of Crizotinib in ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer.克唑替尼治疗ROS1重排晚期非小细胞肺癌的真实世界疗效
Cancers (Basel). 2024 Jan 26;16(3):528. doi: 10.3390/cancers16030528.
6
Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancer.鉴定晚期或转移性非小细胞肺癌患者具有预后和预测价值的非治疗性突变。
Clin Transl Oncol. 2024 Jun;26(6):1384-1394. doi: 10.1007/s12094-023-03362-8. Epub 2024 Jan 6.

本文引用的文献

1
Machine Learning Models for the Identification of Prognostic and Predictive Cancer Biomarkers: A Systematic Review.机器学习模型在预后和预测性癌症生物标志物识别中的应用：系统评价。
Int J Mol Sci. 2023 Apr 24;24(9):7781. doi: 10.3390/ijms24097781.
2
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.晚期 NSCLC 中的联合治疗和 KRASG12C 抑制剂疗效。
Cancer Discov. 2023 Jul 7;13(7):1556-1571. doi: 10.1158/2159-8290.CD-22-1420.
3
Co-Mutation Status Association with Clinical Outcomes in Patients with -Mutant Non-Small Cell Lung Cancer.共同突变状态与EGFR突变型非小细胞肺癌患者临床结局的关联
Cancers (Basel). 2022 Dec 12;14(24):6127. doi: 10.3390/cancers14246127.
4
Fatty Acid Synthase Mutations Predict Favorable Immune Checkpoint Inhibitor Outcome and Response in Melanoma and Non-Small Cell Lung Cancer Patients.脂肪酸合酶突变预示黑色素瘤和非小细胞肺癌患者免疫检查点抑制剂治疗的良好结局和反应
Cancers (Basel). 2022 Nov 17;14(22):5638. doi: 10.3390/cancers14225638.
5
Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Combination Therapy as First-Line Treatment for Patients with Advanced -Mutated, Non-Small Cell Lung Cancer: A Systematic Review and Bayesian Network Meta-Analysis.表皮生长因子受体（EGFR）-酪氨酸激酶抑制剂联合疗法作为晚期突变型非小细胞肺癌患者一线治疗的疗效和安全性：一项系统评价和贝叶斯网络荟萃分析
Cancers (Basel). 2022 Oct 6;14(19):4894. doi: 10.3390/cancers14194894.
6
Radiogenomic System for Non-Invasive Identification of Multiple Actionable Mutations and PD-L1 Expression in Non-Small Cell Lung Cancer Based on CT Images.基于CT图像的非小细胞肺癌中多种可操作突变和PD-L1表达的无创识别放射基因组系统
Cancers (Basel). 2022 Oct 2;14(19):4823. doi: 10.3390/cancers14194823.
7
A Machine Learning-Based Predictive Model of Epidermal Growth Factor Mutations in Lung Adenocarcinomas.一种基于机器学习的肺腺癌表皮生长因子突变预测模型。
Cancers (Basel). 2022 Sep 25;14(19):4664. doi: 10.3390/cancers14194664.
8
Oncogenic EFNA4 Amplification Promotes Lung Adenocarcinoma Lymph Node Metastasis.致癌性EFNA4扩增促进肺腺癌淋巴结转移。
Cancers (Basel). 2022 Aug 30;14(17):4226. doi: 10.3390/cancers14174226.
9
Antiangiogenesis May Not Be a Universal Booster of EGFR Tyrosine Kinase Inhibitors.抗血管生成可能并非表皮生长因子受体酪氨酸激酶抑制剂的通用增效剂。
J Thorac Oncol. 2022 Sep;17(9):1063-1066. doi: 10.1016/j.jtho.2022.06.012.
10
Mutation Association with Immune Checkpoint Inhibitor Outcome in Melanoma and Non-Small Cell Lung Cancer.黑色素瘤和非小细胞肺癌中与免疫检查点抑制剂疗效相关的突变
Cancers (Basel). 2022 Jul 19;14(14):3495. doi: 10.3390/cancers14143495.

肺癌可操作突变的新进展

New Actions on Actionable Mutations in Lung Cancers.

作者信息

Le Xiuning, Elamin Yasir Y, Zhang Jianjun

机构信息

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.

出版信息

Cancers (Basel). 2023 May 26;15(11):2917. doi: 10.3390/cancers15112917.

DOI:10.3390/cancers15112917
PMID:37296880
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10252025/
Abstract

Actionable mutations refer to DNA alterations that, if detected, would be expected to affect patients' response to treatments [...].

摘要

可操作的突变是指那些一旦被检测到，预计会影响患者对治疗反应的DNA改变[……]。